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RUNNING TITLE - Detailed preclinical characterization of triple negative breast 
cancer models 
 
Novelty &Impact 
For the first time, an in depth comparative analysis of two preclinical spontaneously 
metastatic TNBC orthotopic models (MDA-MB-231-Luc and 4T1) is described. We 
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discovered a metastatic switch in both models with immune system activation and serum-
protein profile reconfiguration, which may support resistance to treatment and recurrence in 
TNBC. Importantly, we identified critical functional biomarkers and metabolomic signatures 
for metastasis progression that will facilitate the development of anti-cancer therapeutics. 
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Abstract 
Triple-negative breast cancer (TNBC), an aggressive, metastatic, and recurrent breast cancer 
(BC) subtype, currently suffers from a lack of adequately described spontaneously metastatic 
preclinical models that faithfully reproduce the clinical scenario. We describe two preclinical 
spontaneously metastatic TNBC orthotopic murine models for the development of advanced 
therapeutics: an immunodeficient human MDA-MB-231-Luc model and an 
immunocompetent mouse 4T1 model. Furthermore, we provide a broad range of 
multifactorial analysis for both models that could provide relevant information for the 
development of new therapies and diagnostic tools. Our comparisons uncovered differential 
growth rates, stromal arrangements, and metabolic profiles in primary tumors, and the 
presence of cancer-associated adipocyte infiltration in the MDA-MB-231-Luc model. 
Histopathological studies highlighted the more rapid metastatic spread to the lungs in the 4T1 
model following a lymphatic route, while we observed both homogeneous (MDA-MB-231-
Luc) and heterogeneous (4T1) metastatic spread to axillary lymph nodes. We encountered 
unique metabolomic signatures in each model, including crucial amino acids and cell 
membrane components. Hematological analysis demonstrated severe leukemoid and 
lymphoid reactions in the 4T1 model with the partial reestablishment of immune responses in 
the immunocompromised MDA-MB-231-Luc model. Additionally, we discovered β-
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immunoglobulinemia and increased basal levels of G-CSF correlating with a metastatic 
switch, with G-CSF also promoting extramedullary hematopoiesis (both models) and causing 
hepatosplenomegaly (4T1 model). Overall, we believe that the characterization of these 
preclinical models will foster the development of advanced therapeutic strategies for TNBC 
treatment, especially for the treatment of patients presenting both, primary tumors and 
metastatic spread. 
 
 
 
Introduction  
Triple negative breast cancer (TNBC, lacking progesterone receptor (PR), estrogen receptors 
(ER), and human epidermal growth factor receptor 2 (HER2) expression) represents ~15-20% 
of newly diagnosed cases1 and a complex molecular landscape, low detection rate, and 
aggressive/highly-proliferative nature result in poor prognosis and heterogeneous behavior in 
patients. Rapid growth rates and prominent lymphoplasmacytic inflammatory infiltrates due 
to host immune responses promote metastasis to the lungs, liver, and brain metastasis and the 
frequent lymphatic system involvement that impedes focal treatment, favors recurrence, 
aggravates the clinical situation, and lowers survival rates1. Rapid tumor evolution also leads 
to the development of an inner hypoxic and a subsequent necrotic core2, promoting multiple 
drug resistance (MDR) and poorer prognosis3. 
TNBC currently lacks targeted therapeutics1, and current treatment strategies provide 
heterogeneous responses/outcomes2. Additionally, no standardized treatment for metastatic 
TNBC exists, therefore representing a critical unmet clinical need3. Multistage animal models 
represent crucial translational research platforms for the testing and validation of 
experimental therapies; however, the lack of accurately characterized models that faithfully 
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mimic the pathological features of human TNBC, including spontaneous metastasis or 
multiple side alterations, frequently hampers research4. Currently employed metastatic mouse 
models mimic advanced stage disease, but the requirement for infusions of high 
concentrations of aggressive breast cancer (BC) cells4, the need to resect the primary tumor to 
allow metastasis, or slow metastatic development limits the application of these models. 
We now present the differential features of two preclinically relevant spontaneously 
metastatic TNBC mouse models. First, the well-established 4T1 model5 developed in an 
immunocompetent (BALB/c) background (representing the murine disease) and second, the 
MDA-MB-231-Luc model6 established in immunodeficient (NOD/SCID) background 
(representing the human disease, and more specifically, the mesenchymal stem-like subtype). 
Within this study, we carried out a broad and detailed characterization of disease progression 
in each model and assessed for functional biomarkers, key metabolites, and differential 
cytokines considered crucial for prognosis. Furthermore, we analyzed the suitability for the 
application of preclinical models in the development/translation of advanced therapeutics for 
TNBC treatment, as features such as the enhanced permeability and retention (EPR) effect 
have also been explored6. 
 
 
Materials and Methods 
Cell Culture Conditions 
The 4T1 cell line and MDA-MB-231-Luc cell line were maintained in RPMI1640 media + 
10% heat-inactivated fetal bovine serum (FBS) and DMEM/F12 media (Gibco) + 10% FBS + 
500 µg/mL geneticin (Gibco), respectively, under standard tissue culture conditions. In both 
cases, media was replaced every 2 - 3 days and cells passaged once cultures reached 80% 
confluence. Transfection stability and lack of HER-2, PR, and ER expression in MDA-MB-
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231-Luc cells were confirmed before inoculation (Also, see supplementary information (SI) 
Fig. S1). 
Mouse Strains 
Eight-week-old female inbred immunocompetent BALB/c (BALB/cOlaHsd) mice and the 
immunodeficient non-obese diabetic NOD/SCID (NOD.CB17-Prkdcscid/NCrHsd) mice used 
herein were purchased from Envigo Laboratories Inc. (Spain, EU). 4 to 8 animals have been 
used for each experimental time point.  
Study of the Enhanced Permeability and Retention Effect as a Functional Biomarker 
To study vascular permeability, we followed previously described protocols7. See SI for 
detailed information. 
Establishment of Spontaneously Metastatic Primary Tumor Models 
4T1 orthotopic tumors were induced via subdermal inoculation of 5 x 105 4T1 early passage 
cells suspended in 100 µl of Matrigel (20%) in the second left mammary fat pad of BALB/c 
females under inhalatory anesthesia (3% sevoflurane in 100% oxygen). Following the same 
experimental conditions, MDA-MB-231-Luc tumors were established using 3 x 106 early 
passage cells in NOD/SCID mice. Tumors were morphometrically evaluated daily with an 
electronic caliper and tumor volumes obtained considering a spheroidal tumor shape. 
Metastases in organs of interest in the 4T1 model were isolated and evaluated following a 
previously described protocol5. 
Non-Invasive Imaging Techniques to Monitor Metastasis 
Bioluminescence (BLI) by IVIS® 
MDA-MB-231-Luc cells were tracked using IVIS® technology. For BLI analysis, mice were 
anesthetized and received a subdermal injection of 150 mg/kg D-luciferin (Gold 
BioTechnology, USA). Images were acquired using automatic camera settings and BLI data 
quantified with Living Image software (PerkinElmer, Japan) in terms of photons per second. 
For detailed protocols, see SI. 
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Positron Emission Tomography-Computed Tomography (PET-CT) Analysis 
For PET-CT analysis, animals were kept without food for 14 h before radiotracer 
administration for PET and housed at a constant temperature of 21ºC. The average mouse 
weight was 19.2±0.7g, while the average blood glucose level was 47.2±10.1 mg.dl-1. 
Anesthesia was induced by inhalation of isoflurane (4% in 100% oxygen) and maintained at 
(1.5% in 100% oxygen). See SI for further details. 
Blood Collection and Analysis 
At defined time points, mice were sacrificed under a CO2 atmosphere. Blood was 
immediately extracted by cardiac puncture. Serum was isolated and analyzed using an 
automated hematologic analyzer (Sysmex XT-2000i). Serum protein content was measured 
using an automated capillary electrophoresis system (Capillarys 2, Sebia, France). See SI for 
additional details. 
Histopathological Analysis and Imaging 
Histopathological analysis employed conventional tissue preparation and paraffin inclusion 
(see SI). Tissue slides of interest were scanned with a Panoramic 250 Flash III slide scanner 
and processed with CaseViewer software (3DHISTECH Ltd, Budapest, Hungary). We 
provide a detailed list of the antibodies employed in the SI section (Fig. S11). 
Metabolomics Profiling by NMR 
Metabolomic sampling and processing were carried out according to previously described 
protocol8. See SI for further details. 
Exosome Isolation, Measurement, and Quantification from Mouse Blood Serum 
Serum exosome isolation was performed by serial differential centrifugations of fresh serum 
isolated from blood through centrifugation (see SI for details of the process). For exosome 
measurement and quantification, purified exosomes were diluted with PBS buffer (100 – 
5000 times) to reach a particle concentration in the operational range for nanoparticle 
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tracking analysis (NTA) (2 x 108 – 2 x 109 particles/ml). Exosomes were then quantified and 
measured using the Nanosight NS300 (Malvern Instruments, UK). 
Results 
Comparison of TNBC Model Primary Tumor Development 
Primary morphological analysis demonstrated that 4T1 tumors grew exponentially and 
homogeneously, reaching a cylindrical form after day (D)24 (Fig. S2). Subsequent analysis 
demonstrated slower initial growth kinetics for MDA-MB-231-Luc tumors compared to 4T1 
up to ~D30, finally acquiring an amorphous cylindrical shape at D42 (Fig. S2). Primary 
tumors in both models exhibited the typical stromal progression of most solid tumors, 
including inner necrotic region development9, although with marked differences in growth 
kinetics and stromal arrangement (Fig. S3A, B). 
Analysis of tumors at the experimental endpoints demonstrated that the internal necrotic 
tissue presented cellular debris with diffuse margins, pyknotic nuclei, and karyorrhexis in 
both models (See H&E sections in Fig. 1A, B). While H&E tumor sections in 4T1 tumors 
identified a spheroidal concentric necrotic core surrounded by homogeneous concentric 
transition rings followed by a concentric proliferative region, MDA-MB-231-Luc tumors 
presented a more gelatinous necrotic core with heterogeneous spread of necrosis throughout 
the tumor stroma (Fig. 1A, B). Overall, the stroma surrounding MDA-MB-231-Luc tumors 
presented lower cellular density and tumors evolved as soft and flexible solid masses (Fig. 
S3A, B). Both animal models developed fungating lesions (round, non-bleeding skin 
ulcerations with firm inflamed borders above the mammary gland) that appeared during the 
first week of 4T1- and the second week of MDA-MB-231-Luc-tumor development, in line 
with human wound development subtypes10 (Fig. S2).  
Cytokeratin (CK)-AE1/AE3 immunostaining confirmed the epithelial nature of tumor cells, 
with expression varying between both region, and model. Factor VIII immunostaining 
demonstrated similar tumor neovasculature and undamaged endogenous blood vessels in both 
models, indicating a slightly vascularized tumor stroma (Fig. 1A, B). We subsequently 
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evaluated region-dependent proliferative rates by Ki-67 immunostaining and confirmed 
increased cell growth rates in outer regions of both tumors. We summarize data on 
immunohistochemical tumor markers in Fig. S3A. 
We also morphometrically evaluated volume during tumor development in both models, 
discovering marked differences in growth kinetic profiles (Fig. 1C). We observed a ~2-fold 
greater tumor growth rate for the 4T1 model (reaching ~1.0 cm3 at D24) when compared to 
the MDA-MB-231-Luc model (reaching ~1.0 cm3 at D42), despite notable differences in the 
number of inoculated cells (5 x 105 vs. 3 x 106, respectively).  
Subsequent quantification of maximum tumor permeability (related to the EPR effect7) 
established three-fold greater permeability for the MDA-MB-231-Luc model when compared 
to the 4T1 model (33% injected dose (ID)/gram of tumor (g) at ~D14 vs. 13% ID/g at D10, 
respectively, when analyzing tumors at ~0.1 cm3) (Fig. 1D).  
Tumor density analyses reflected differential stromal arrangements, as previously noted (Fig. 
1E). 4T1 tumors initially displayed high density at early development time points (~3 g/cm3), 
which then decreased progressively over two weeks to ~1.5 g/cm3. In contrast, MDA-MB-
231-Luc tumors displayed a more homogeneous density during tumor development, rising 
from 1.0 g/cm3 to 1.4 g/cm3 over the experimental time frame. 
Additional metabolomics analysis supported differences in tumor growth kinetics observed 
between models; 4T1 tumors displayed increased levels of guanosine and uracil (metabolites 
related to cell growth and proliferation, Fig. 1F, G) and cholesterol and phospholipids 
(critical cell membrane components, Fig. 1H, I), when compared to the MDA-MB-231-Luc 
tumors. 
Importantly, the tumor histopathological study at model endpoints also demonstrated a 
relationship between MDA-MB-231-Luc tumors, but not 4T1 tumors, and lipid burden (Fig. 
1A, B). We observed disperse accumulation of adipocyte lobes from early stages of MDA-
MB-231-Luc tumor development, with adipocytes distributed throughout the proliferative 
tumor region (Fig. S3B, C). According to their reduced size and distribution pattern within 
the tumor stroma and further Interleukin (IL)-6 and IL-1β immunostaining11, 12 (Fig. 1J), we 
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consider these adipocytes as cancer-associated adipocytes (CAA). Interestingly, metabolomic 
comparisons revealed significantly increased triacylglycerol (TAG) levels for MDA-MB-
231-Luc tumors, a lipid whose synthesis/hydrolysis is controlled by adipocytes, agreeing with 
histopathological findings (Fig. 1H, I). 
Comparison of TNBC Model Spontaneous Metastatic Landscape 
4T1 tumors metastasize to liver, lungs, bones, and brain at advanced stages, and we employed 
intrinsic resistance to 6-thioguanine (6-TG) to quantify metastatic cells13. MDA-MB-231-Luc 
tumors produce multiple organ metastasis after intravenous cancer cell inoculation or after 
tumor resection14; however, to the best of our knowledge, no study has reported spontaneous 
metastatic spread from unresected MDA-MB-231 tumors in NOD/SCID mice (e.g., see Ref. 
15). In both models, we observed a very low incidence of brain, bone, and liver metastases, 
but high levels of lung and axillary lymph node (ALN) metastasis (Fig. 2), a finding that 
correlates with the TNBC clinical scenario. Therefore, our studies focused on these two 
major metastatic sites.  
Lungs from the 4T1 model revealed evident sub-pleural metastases from D8, although we 
discovered the first evidence of discrete micro-metastasis from D3 (Fig. S4). Between D8 to 
D16, lungs presented with perivascular metastatic nodules following a predominantly sub-
pleural pattern16. H&E staining identified prominent metastatic progression leading to 
disperse necrotic regions from D14 (Fig. 2A). Additionally, macroscopic examination 
identified increased tissue hyperemia concomitant with metastasis progression; however, we 
did not observe this trend in MDA-MB-231-Luc lungs (Fig. 2B).  
Metastatic burden in MDA-MB-231-Luc appeared later than in the 4T1 and exhibited higher 
variability. Macroscopic lung evaluation uncovered first signs of lung metastases at ~D28 as 
homogeneously disperse nodes, with intraalveolar and intrabronchiolar metastatic 
infiltrations present throughout the lung parenchyma (Fig. 2A, B). Subsequently, lungs 
became slightly hyperemic and displayed signs of damage (Fig. 2B). We confirmed 
metastasis and enhanced proliferation in both models using CK-AE1/AE3 and Ki-67 
immunostaining, respectively (Fig. 2A, B, and Fig. S3A, C). Overall, we observed higher 
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lung metastasis and lesser implication of the subpleural region in the MDA-MB-231-Luc 
compared to the 4T1 model. 
Comparisons of healthy and metastatic lungs at the metabolomics levels established 
significant alterations in both models. Analysis of corresponding Orthogonal Projections to 
Latent Structures Discriminant Analysis (OPLS-DA) models revealed similar metabolic 
changes for the 4T1 and MDA-MB-231-Luc models (e.g., taurine, glutamate, UDP-N-
acetylglucosamine), while other metabolites experienced variations of opposite sign (e.g., 
lysine, tyrosine). Furthermore, comparisons between metastatic and healthy lungs also 
uncovered several unique metabolic changes (e.g., 4T1: phenylalanine, arginine, aspartate; 
MDA-MB-231-Luc: glutathione, glycerophosphocholine) (Fig. 2C-F). 
At the macroscopic level, inguinal lymph node (ILN) metastases appeared in most 4T1 
animals, and those with ILN metastases suffered from rapid ALN spread. Direct ALN 
metastasis without ILN involvement rarely occurred (Fig. 2C). However, we seldom found 
metastases on the right side of the body (side of inoculation) and so we focused on metastatic 
development from tumor to left ALN following the afferent lymphatic vessel. 4T1 ALNs 
appeared macroscopically normal until D17, after which we observed metastasis (Fig. 2G). 
Histopathological studies revealed nodes with varying degrees of physiological activation and 
swelling in the absence of metastasis until D10, and the majority of mice displayed similar 
characteristics by the endpoint (Inset Fig. 2G). However, some 4T1 tumor-bearing mice 
exhibited paracortical metastatic foci within the node hilus from D13. Mice with similar 
characteristics displayed widespread metastatic invasion of the ALN at D20 of tumor 
development. By D24, mice exhibited almost complete ALN invasion with normal 
morphology loss. 
MDA-MB-231-Luc model macroscopic studies discovered lower variability in ALN invasion 
when compared to the 4T1 (Fig. 2H). We observed no signs of metastatic spread in the first 
three weeks of MDA-MB-231-Luc tumor development; however, all ALNs presented with 
signs of medullary sinusoidal metastasis at D21-28 (inset Fig. 2H). As expected, ALN 
swelling directly correlated to metastasis due to the lack of lymph node immunoreactivity and 
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immune-related swelling. We also discovered more prominent metastasis to the left ALN in 
the MDA-MB-231-Luc model at advanced tumor development stage (Fig. 2H). Figure S3 
and S4 summarize findings related to primary tumor and spontaneous metastasis landscape 
and Figure S5 depicts time-frame metastatic spread in MDA-MB-231 ALNs. 
Non-invasive imaging of Primary Tumor and Metastasis Development in TNBC Models 
18F-fluorodeoxyglucose uptake by positron emission tomography (18F-FDG-PET) and 
computed tomography (CT) permitted in vivo analysis of 4T1 tumor progression17. Figure 
3A depicts a three-dimensional view of tumor development displaying uniform radiotracer 
uptake by the spheroidal tumor mass until D3. We observed the development of an inner 
tumor core from D10, growing concentrically within the tumor mass, confirming previous 
findings (Fig. S3) and coinciding with maximal EPR effect (Fig. 1D). Analysis displayed in 
Figure 3A confirmed tumor core necrosis via the lack of radiotracer uptake. At endpoint, the 
necrotic region constituted ~80% of total tumor volume, and PET analysis confirmed 
metastasis in the left ALN only (Fig. 3B, Fig. S6). 
Inherent luciferase activity in MDA-MB-231-Luc cells permitted the in vivo tracking of 
tumor progression and quantification of distal metastasis by bioluminescence imaging (BLI) 
using the IVIS® system (Fig. 3C). Tumors grew uniformly until D28, after which they 
became amorphous, with a loss of bioluminescence, again evidencing the necrotic core. 
Figure 3C also confirmed the uniform appearance of left ALN metastasis at D28 as 
demonstrated by histopathology (Fig. 2D). BLI analysis at D35 revealed increased left ALN 
metastasis with extravasation to the right ALN, the advancement of tumor core necrosis, and 
metastatic spread to surrounding tissues (Fig 3C). At endpoint, all mice displayed increased 
metastatic growth to the left ALN, invasion of the right ALN, and metastatic growth 
development in abdominal and thoracic regions (Fig. S6).  
Dynamic PET/CT analyses demonstrated a hypodense region within MDA-MB-231-Luc 
tumors at endpoint (Fig. 3D - red arrow); however, we observed a thinner 18F-FDG labeled 
ring in the peritumoral region indicative of lower glucose metabolism at the tumor site. 
Additionally, we observed evidence of radiotracer uptake in abdominal lymph nodes around 
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the tumor site (Fig. 3D inset). Fig. 3E shows significantly swollen left ALNs by CT. By PET, 
we detected the expected metastatic growth with the highest uptake located close to the 
afferent region of the left ALN and metastatic spread to the right ALN in the absence of 
swelling (as shown by CT) (Fig. 3E - yellow arrows). By CT, we also observed lung 
metastasis following the so-called miliary pattern18, which describes innumerable small 
metastases of variable-size within the parenchyma (Fig. S4C; consistent with Fig. 3E). 
Comparison of TNBC Model Hematological Parameters  
The hematological study depicted the development of systemic pathologies during tumor 
growth, including a marked tumor-derived inflammatory response with anemia, 
thrombocytosis, reticulocytosis, leukocytosis, and subsequent lymphocytosis (Fig. 4 and Fig. 
S7). This profile evolved during tumor development, although we observed model-specific 
alterations related to immune system status with significantly higher levels of 
leukocytes/lymphocytes at later stages in the 4T1 model (Fig. 4). Both models exhibited 
reduced erythrocyte levels (~8-10%) during tumor development, correlating to imbalanced 
medullary/extra-medullary hematopoiesis (Fig. 4A, B). We found more pronounced anemia 
in the 4T1 model with hemoglobin levels diminishing gradually (Fig. S7). Although more 
pronounced in the 4T1 model, we also discovered a robust increase in reticulocytes in both 
models; however, in contrast, we found significantly higher thrombocyte levels in the MDA-
MB-231-Luc model (~800 g.L-1 vs. ~ 400 g.L-1) at endpoints (Fig. 4A, B). 
While a severe leukemoid reaction occurred from D10 in the 4T1 model (~160 g.L-1), we 
only observed a slight effect in the MDA-MB-231-Luc model (~27 g.L-1) close to endpoint 
(Fig 4A, B). In both models, segmented neutrophils accounted for ~33% of leukocyte number 
before tumor cell inoculation and ~85% at the endpoints. We also observed a differential 
lymphoid reaction between the models, in agreement with leukocyte counts. Wright-stained 
blood smears confirmed results by allowing comparisons with data from healthy mice with 
tumor model endpoint data (Fig. S7). Although we observed a more moderate response in 
MDA-MB-231-Luc, both models exhibited extensive granulocytosis (left shift) with 
predominant levels of polynuclear-segmented leukocytes. 
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Immunophoretic analysis of blood serum revealed a significant and sudden increase in 
gamma-globulin and alpha-2-globulin levels and a decrease in albumin levels at D42 in the 
MDA-MB-231-Luc model (Fig. 4C). Moreover, we found increased beta globulin bands in 
4T1 (D3) and MDA-MB-231-Luc (D35) models, coinciding with the first evidence of lung 
metastasis (Fig. 4C, D). 
Exosomes play crucial roles in conditioning the pre-metastatic niche19, and we employed 
NTA of peripheral blood serum to assess exosomal dynamics during tumor progression. We 
discovered peak exosome levels on the first appearance of metastasis (D3) in 4T1 (Fig. 4E, 
S8), before returning to basal levels. However, we did not observe any fluctuations during 
tumor progression in the MDA-MB-231-Luc model. 
Directly correlated with the immune system status, inflammatory response markers may 
predict clinical outcomes in cancer patients, and so, we evaluated the neutrophil-lymphocyte-
ratio (NLR), finding a rapid increase from D6 in the 4T1 model (Fig. 4F). As an innate 
immune system effector, the complement system constitutes the first barrier against non-self-
cells and plays a decisive role in tumor growth20. In agreement, 4T1 animals displayed 
increasing levels of C-3 protein from D20 (Fig. 4G). 
Dysregulated Bone Marrow Hematopoiesis in TNBC Models: A role for G-CSF in 
Extramedullary Hematopoiesis 
Initial macroscopic organ analysis indicated acute splenomegaly (0.6% to 4% total body 
weight from D6 to D24) and slight hepatomegaly (4.8% to 6% total body weight over 24 
days) (Fig. S9A, B) in the 4T1 model21, but not the MDA-MB-231-Luc model. 
Histopathological studies of bone marrow uncovered reduced megakaryocytosis (Factor 
VIII), reduced myeloid cell precursors (myeloperoxidase), and enhanced granulocytosis (CD-
15) compared to healthy tissues (Fig. 5A), supporting extramedullary hematopoiesis (EH) 
promoted by bone marrow myelosuppression (in agreement with previous hematological 
findings). Analysis of the enlarged spleen of the 4T1 model supported EH by reactive 
megakaryocytic hyperplasia, as evidenced by large numbers of Factor VIII-positive 
megakaryocytes, and ongoing erythropoiesis, as evidenced by Glycophorin A-positive 
This article is protected by copyright. All rights reserved.
erythroid-precursors and mature erythrocytes (Fig. 5B). Further studies revealed increased 
cellularity and congested red pulp with hyperplasia due to elevated reactive hematopoiesis 
(Fig. S9C, D). Studies of the MDA-MB-231-Luc model normal-sized spleen highlighted 
reactive megakaryocytic hyperplasia as the unique pathological consequence of EH (Fig 5B).  
In the 4T1 model, we observed overt signs of EH in the liver, as evidenced by increased 
myeloid precursor cell22-24 (MPC) perivascular infiltration into the surrounding hepatic 
arteries starting from D3 (Fig. S9E). At later stages, MPCs entered the liver parenchyma to 
induce reactive megakaryocytic hyperplasia (Figure 5B). In contrast, MDA-MB-231-Luc 
model liver developed no significant macroscopic or histopathological abnormalities (Fig. 
5B). 
To understand EH origin, we conducted immunoassays to analyze circulating granulocyte 
colony stimulating factor (G-CSF) levels25. We discovered increasing levels of total G-CSF 
in 4T1 model peripheral blood at early stages of tumor development (Fig. 5C), in agreement 
with previous studies in immunocompetent mouse models26. We also discovered increasing 
levels of tumor- and host-derived G-CSF during MDA-MB-231-Luc tumor progression (Fig. 
5C). Of note, only in vitro studies have previously shown G-CSF secretion from MDA-MB-
231 cells27. High human G-CSF levels in MDA-MB-231-Luc started increasing from D28 
(Fig. 5D) and correlated to the previously observed leukemoid/lymphoid reactions. 
Discussion 
The accelerated development of advanced anti-cancer therapies requires preclinical models 
and the identification of functional biomarkers to facilitate clinical translation28 and 
identification of patients who could benefit from therapies29. In this study, we report the 
exhaustive characterization of relevant preclinical TNBC mouse models regarding systemic 
landscape, metastatic foci, and metabolic alterations, paying particular attention to functional 
biomarkers. Both models develop homogeneous primary tumors with subsequent ALN and 
lungs metastasis, faithfully mimicking critical features of the human disease. Therefore, these 
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models offer a useful platform for testing/validation of advanced anticancer therapeutics, 
especially for the treatment of patients presenting with both primary tumors and metastasis. 
Modeling Capacities of the 4T1 and MDA-MB-231-Luc TNBC Models 
The rapid tumorigenic development encountered for the 4T1 model offers a rapid and 
straightforward means to assess treatment outcomes in an immunocompetent model. Model 
characteristics include aggressive primary tumor evolution as densely packed masses with 
slight anemia, thrombocytosis, and reticulocytosis in the short term, and an acute leukemoid 
reaction with lymphocytosis and complement system activation in the mid-to-long term. In 
comparison, the MDA-MB-231-Luc model displayed slower tumor growth with marked 
spontaneous inclusion of CAAs, known to exhibit an activated phenotype linked to the 
acquisition of a pro-invasive effect of surrounding tumor cells12. Therefore, high CAA 
content of MDA-MB-231-Luc tumors may serve as a faithful model to study this 
phenomenon and develop treatments to avoid adipocytic pro-tumorigenic effects. 
Furthermore, high lipid content and low cellular density in the tumor stroma generated a 
softer tumor mass with a three-fold higher EPR effect, thereby providing a model to assess 
EPR-related passive tumor accumulation, especially important for the effectiveness of 
nanomedicinal approaches to cancer treatment7, 30, 31. The flexibility and permeability of the 
MDA-MB-231-Luc model stroma may also provide a means to assess intratumoral 
administration strategies32. 
The metabolomic comparison of 4T1 and MDA-MB-231-Luc primary tumors suggests that 
specific metabolic alterations could explain the differences observed in growth rates, with 
guanosine and uracil (a pyrimidine derivative) the two most relevant soluble metabolites 
contributing to model discrimination. Interestingly, Tayyari et al.33 reported that TNBC 
tumors displayed increased pyrimidine synthesis and elevated levels of myoinositol and 
taurine, similar to findings in our 4T1 primary tumors. Metabolomic analysis of organic 
extracts provided further evidence for lipidic reprogramming in TNBC development and 
progression; in particular, 4T1 primary tumors displayed higher concentrations of cholesterol 
and phospholipids. These alterations reflect the avidity of proliferative cancer cells for lipids 
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and cholesterol34, a characteristic now considered a hallmark of cancer aggressiveness34, 35. 
MDA-MB-231-Luc primary tumors also displayed high levels of TAGs, whose hydrolysis in 
adipocytes adjacent to cancer cells generates free fatty acids for use as an energy source by 
tumor cells for tumor progression34 .  
We observed spontaneous lung and ALN metastasis in both models; however, while studies 
suggest that the 4T1 model develops lung metastasis via the hematogenous route13, we 
discovered earlier evidence of distal metastasis and subsequent rapid development 
predominantly through the lymphatic system, as observed in two recent studies36, 37. 
Therefore, the 4T1 mouse model is ideal for the development and validation of lymph-
targeted anti-cancer therapies38. Additionally, alterations to the complement system in the 
4T1 model may provide a prognostic marker of disease progression or even a sign of 
treatment efficiency when using non-immunogenic therapeutics (a safety requirement for 
systemic administration).  
The Role of G-CSF as a Critical Functional Biomarker of Metastatic Progression 
The colony-stimulating factor (CSF) subfamily of glycoproteins play crucial roles in 
inflammatory cell activation39, bone marrow cell mobilization into the peripheral blood, and 
immune system activation40. Increasing levels of G-CSF during 4T1 tumor progression26 may 
trigger passive compensatory EH and the concomitant leukemoid reaction with prominent 
hepatosplenomegaly26. The leukemoid reaction is a well-described paraneoplastic affection, 
arising in ~15% of cancer patients, proposed as a prognostic marker for BC41 thereby 
ratifying the suitability of our 4T1 model as preclinical BC model. 
The MDA-MB-231-Luc model presented similar hematological parameters to the 4T1 model 
at early stages; however, we did not observe a leukemoid reaction accompanying tumor 
growth, and the first evidence of metastasis occurred at later time points through the 
hematological pathway. Importantly we observed that tumor- and host-derived G-CSF release 
concomitant with metastasis, led to the partial restoration of the immune system 
(granulocytosis and lymphocytosis) suggesting a “metastatic switch” appearing from the 
fourth week to trigger an immunological response in the immunosuppressed NOD/SCID 
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mouse model. This suggests that stromal cells and/or host tumor-infiltrating cells also 
represent a significant G-CSF source42. Although the reduced immunological competency of 
the host does not permit extended adaptive splenomegaly or hepatomegaly in this model, we 
observed slight passive EH in the spleen as a response to bone marrow myelosuppression. 
Surprisingly, we only observed lung metastasis from D28, concomitant with human G-CSF 
release. Studies have proposed the indirect role of G-CSF in pre-metastatic niche formation43, 
a finding supported by our MDA-MB-231-Luc model discoveries. Therefore, we propose 
circulating G-CSF levels as a prognostic indicator of disease and more importantly, the 
inhibition of cytokines such as CSFs as a promising therapeutic approach alone or in 
combination with metastatic inhibitors. We do note that the possible role of either human or 
host G-CSF in the immune system reactivation of the NOD/SCID mice remains unresolved; 
although the leukemoid reaction triggered by the release of G-CSF may be responsible for 
metastasis spread. 
Our work emphasizes the active role of the immune system in metastatic spread in both 
models44. We suggest, after the sudden changes at week four, that a quiescent MDA-MB-
231-Luc tumor subpopulation reactivates through a likely “metastatic switch”. Several tumor-
derived factors could be involved in the generation of pre-metastatic niche, and their 
overexpression could be a prerequisite for metastasis development. 
Other Biomarkers and Predictive Factors 
Exosomes have emerged as regulators of inter- and intra-cellular communication and can 
“tailor” the pre-metastatic niche for engraftment of cancer cells19. Interestingly, the 4T1 
model displayed significantly increased circulating blood exosomes at D3, simultaneous with 
the first evidence of lung metastasis, suggesting its active role in lung metastasis 
establishment19. However, we did not find any modulation in exosome levels in MDA-MB-
231-Luc.  
The prompt hyper-β-immunoglobulinemia detected in both models coincided with first signs 
of lung metastasis. Transferrin overexpression may be connected to neovascularization to 
influence metastatic capacity in BC45. Transferrin-like lipoproteins can specifically stimulate 
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metastatic cell growth46. Similarly, β-lipoprotein (LDL) is intimately involved in angiogenic 
regulation, with a direct connection between LDL levels and metastatic progress47. In this 
context, our metabolomics analyses confirmed that lipid metabolism alterations closely 
associates with TNBC malignancy and metastatic progression to the lungs. 
Finally, studies have demonstrated that NLR associates with poorer prognosis in human 
cancers48; high NLR associates with reduced disease-free survival (DFS). Applying this 
prognostic factor in our 4T1 model, NLR values indicate worse prognosis from D6-10, 
mimicking advanced stages of the disease and providing a tool to develop therapeutics 
devoted to recurrent or metastatic scenarios. 
Metabolomic Metastatic Signature  
Metabolomic analysis of lung tissues revealed distinct signatures for both models. Some 
metabolites exhibited the same trend when comparing metastatic and healthy lung tissues 
(taurine, glutamate, UDP-NAG, glucose), reflecting common alterations. For example, the 
metabolism of glutamate/glutamine and taurine/hypotaurine plays a significant role in 
TNBC33 and UDP-derivatives have been linked to metastasis49. A second important group of 
metabolites, mostly composed of amino acids, exhibited changes in the opposite direction 
when comparing metastatic and healthy lung tissues. The differences in amino acids levels 
may relate to different growth kinetics; much faster for the 4T1 model therefore requiring 
more energy. Of note, several amino acids that exhibited lower concentrations in the MDA-
MB-231-Luc model metastatic lung (i.e., leucine, isoleucine, and valine) are branched amino 
acids (BCAA) and studies have indicated an association between increased concentrations of 
BCAA and chemotherapy-induced apoptotic processes8. Interestingly, the ratio of 
choline/GPC indicates the acidic nature of metastatic tumors, since lower pH (typical of 
tumor cells) leads to decreased PC and increased GPC50. High glutamine consumption 
correlates with the essential function of glutaminase in TNBC development51. Decreased 
creatine phosphate levels, perhaps related to hypoxic regions within the metastasis52, also 
correlate with the reduced pH characteristic of tumors. 
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We also found several unique metabolic changes for each model. In 4T1 metastatic lungs, we 
discovered increased phenylalanine levels53 (related with advanced stages of the disease), 
aspartate8 (upregulated glutaminolysis) and ATP+ADP (fueling metastatic survival). Analysis 
of MDA-MB-231-Luc metastatic lungs revealed a specific increase in glutathione levels, a 
molecule that plays protective and pathogenic roles and promotes chemoresistance54, and 
GPC levels. Overall, the metabolomic signature for lung metastases in each model reflects 
the different molecular and biochemical mechanisms associated with metastatic spread, 
which could be employed as a biomarker for disease monitoring during preclinical evaluation 
(see also Fig. S10). 
One limitation of this study lies in the characterization of only one subtype, representing 
~15% of all TNBC types. Therefore, a similar analysis of other TNBC subtypes would 
provide additional information that could be relevant from a clinical standpoint. We are also 
aware of the lack of tumor resection during the characterization of the metastatic spread to 
lungs, an intervention that would also closely mimic the clinical situation. Nevertheless, we 
believe that studying metastasis in the presence of the primary tumor could aid the 
development of therapies for patients exhibiting both tumor modalities, who currently lack 
adequate preclinical models. 
Conclusion 
Within this present study, we describe the progression of two preclinical spontaneously 
metastatic TNBC models relevant for the development of anti-cancer therapeutics (summary 
of main features in Figure 6). We concentrated on the pathological features that ultimately 
drive anti-cancer treatment and, therefore, patient outcomes. Our exhaustive characterization 
demonstrated MDA-MB-231-Luc metastatic progression in the NOD/SCID model. We also 
discovered a metastatic switch in both models (MDA-MB-231-Luc and 4T1) with immune 
system activation and serum-protein profile reconfiguration, which may support resistance to 
treatment and recurrence in TNBC. The detailed characterization of relevant models such as 
these will help to foster the rational design of anti-cancer therapeutics. Importantly, we 
identified critical functional biomarkers including the EPR effect, G-CSF, CAA infiltration, 
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NLR, complement activation, and metabolomic signatures for metastasis progression that 
may further facilitate the development of anti-cancer therapeutics. 
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FIGURE LEGENDS 
Figure 1. Primary tumor development and immunohistological analysis of features. A) 
and B) Axial tumor H-E staining, demonstrating stromal arrangement and 
immunohistochemical study (CK-AE1-AE3, Factor VIII, and Ki-67) of tumor regions. 
Original magnification displayed in each image. C) Morphometric tumor analysis 
demonstrating differential grow kinetics of primary tumors in both models. D) EPR effect 
quantification of primary tumors. EPRMAX was around 0.1 cm3 for both tumor models, 
corresponding to D8 and D14 for 4T1 and MDA-MB-231-Luc, respectively. E) Tumor 
density determined by simple arithmetic calculation demonstrating a lighter stroma as result 
of lower cellular density and higher lipid content in the MDA-MB-231-Luc model. F) 
Multivariate modeling resulting from the analysis of primary tumors (F and H) OPLS-DA 
score plot representing the comparison between MDA-MB-231-Luc vs. 4T1 primary tumors 
(aqueous phase) (R2 = 0.976 / Q2 = 0.925) and organic phase (R2 = 0.982 / Q2 = 0.936), 
respectively. G and I) Metabolic changes for MDA-MB-231-Luc vs. 4T1 primary tumor 
(aqueous phase) and MDA-MB-231-Luc vs. 4T1 primary tumors (organic phase) 
comparisons. Statistical significance determined via ANOVA t-test, (*** p<0.001, ** 
p<0.01, *p<0.05). J) Representative images of CAAs with H&E staining and 
immunostaining with IL-1β and IL-6. CAAs from MDA-MB-231-Luc tumors exhibited 
extensive phenotypic changes. Subpopulations of adipocytes that infiltrated within tumor 
stroma expressed IL-1β and also IL-6 (but to a lesser extent)(CAAs indicated with red arrow 
heads). Note the diminished averaged sizes, a known characteristic feature of CAA. 
Figure 2. Spontaneous lung and ALN metastatic development and immunohistological 
analysis. A) Representative images of 4T1 model lungs over time after necropsy and staining 
with H&E and immunostaining with CK-AE1/AE3 and Ki-67. 4T1 model lungs presented 
with prominent subpleural metastasis from D8 after tumor cell inoculation. Further analysis 
confirmed predominant pleural invasion, although intraparenchymal regions also appeared 
metastasized. Metastatic regions within the lungs as evidenced by CK-AE1/AE3 
immunostaining and highly proliferative nature evidenced by Ki-67 immunostaining. B) 
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Representative images of MDA-MB-231 model lungs over time after necropsy and staining 
with H&E and immunostaining with CK-AE1/AE3 and Ki-67. The MDA-MB-231-Luc 
model developed metastasis later (D28) and the metastatic nodules appears disseminated 
throughout the lung parenchyma with predominant bronchioloalveolar pattern. Multivariate 
modeling resulting from the analysis of lung metastases. (C and D) OPLS-DA score plot 
representing comparisons between healthy lung tissue vs. metastatic lung (4T1) (aqueous 
phase; R2 = 0.913 / Q2 = 0.890) and healthy lung tissue vs. metastatic lung (MDA-MB-231-
Luc) (aqueous phase; R2 = 0.921 / Q2 = 0.806), respectively. E) and F) Metabolic changes for 
healthy lung tissue vs. metastatic lung (4T1) (aqueous phase) and healthy lung tissue vs. 
metastatic lung (MDA-MB-231-Luc) (aqueous phase) comparisons, respectively. Statistical 
significance determined via ANOVA t-test, (*** p<0.001, ** p<0.01, *p<0.05). G) Evolution 
of ALN metastasis with time by H&E staining and CK-AE1/AE3 and Ki-67 immunostaining. 
The 4T1 model displayed heterogeneous metastatic invasion in ALN. The vast majority of 
animals presented metastasis in the left ALN at the experimental endpoint H) The MDA-MB-
231-Luc model exhibited homogeneous ALN metastasis distribution. Left and right ALN are 
shown. 
 
Figure 3. Non-invasive imaging techniques for in vivo visualization of primary tumor 
and metastatic landscape. A) PET/CT combination permitted in vivo monitoring of 4T1 
primary tumor progression. Image reconstruction of overlapped CT and PET image 
acquisitions. Regions with different radiotracer uptake levels have been colored to facilitate 
interpretation: green: bladder identification (max 18FDG caption); blue: tumor region 
identified by CT with high 18FDG uptake. Red: tumor region identified by CT with low 
18FDG uptake rate.  Note the increasing hypodense region developing in the tumor core 
corresponding to the necrotic core. B) ILN invasion observed close to the experimental 
endpoint, as seen in the axial projection of a representative 4T1 mouse. However, lung 
metastasis was not observed under our experimental conditions. C) Tumor growth and 
metastatic landscape demonstrated by BLI in the MDA-MB-231-Luc tumor model. ALN 
metastasis noted from D28, and tumor necrotic core noted from D35. D) Three-dimensional 
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projections of an MDA-MB-231-Luc representative mouse at the experimental endpoint. CT 
allowed for the delimitation of the tumor region (green region). Further PET analysis 
permitted the visualization of the peritumoral region, displaying a dark hollow indicative of 
tumor necrosis (inset, red arrow). Moreover, ILN metastasis was detectable with higher 
prominence on the left side (yellow arrows). E) Thoracic region in detail. Characteristic 
intraparenchymatous lung metastasis detected by CT (green arrows). In addition, the swollen 
left ALN detected by CT (red region), but only an active metastatic region was detected by 
PET (yellow region) within the ALN mass. 
 
Figure 4. Hematological changes during tumor progression. Complete hemogram of 4T1 
model (A) and MDA-MB-231-Luc (B). Proteinograms of peripheral blood in both models 
during tumor progression displayed in C) and D). Beta hyperglobulinemia found in both 
models at the same time that lung metastasis evolved (D3 for the 4T1 model and D35 for the 
MDA-MB-231-Luc model). Data represent mean ± SEM. Statistical significance was 
determined via ANOVA t-test, (*** p<0.001, ** p<0.01, *p<0.05) The MDA-MB-231-Luc 
model displayed acute bands in the alpha immunoglobulin and gamma immunoglobulin, a 
profile compatible with ongoing inflammatory processes (increased alpha-2 globulin), while 
the unspecific hypoalbuminemia is consistent with any previously mentioned pathologies in a 
chronic scenario. E) Comparison of circulating exosome levels, quantified by NTA between 
both tumor models over time F) Neutrophil/Lymphocyte ratio (NLR). The MDA-MB-231-
Luc mouse NLR is included for comparative purposes, although the immunocompromised 
character of the NOD/SCID mice does not permit a proper comparison. G) C3 complement 
system activation in the 4T1 tumor model. 
 
Figure 5. Extramedullary hematopoiesis promoted by G-CSF occurred to a different 
extent between models and triggered mobilization of different myeloid precursors. In the 
first instance, G-CSF impedes the normal maturation of myeloid cell precursors in bone 
marrow (A). Representative images of bone marrow in healthy and experimental end points, 
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staining with H&E and immunostaining with Factor VIII, Myeloperoxidase, and CD-15. (B) 
4T1 and MDA-MB-231-Luc cells secrete G-CSF, which blocks normal bone marrow 
hematopoiesis and activates extramedullary hematopoiesis by stimulating the release of 
immature myeloid precursors. The 4T1 model presented hepatosplenomegaly as result of 
erythropoiesis (Glycophorin A +) and megakaryopoiesis (Factor VIII +) in the spleen and 
also megakaryopoiesis in the liver. Additionally, multiple colonies of myeloid cell precursors 
were found in the liver. The MDA-MB-231-Luc model does not present with erythropoiesis-
related hepatosplenomegaly (Glycophorin A –, in spleen and liver); however, prominent 
megakaryocytes were found in the spleen, as a result of strong megakaryopoiesis. (C) Levels 
of G-CSF in the 4T1 model over time. (D) Levels of human and murine G-CSF in the DA-
MB-231-Luc model at progressive time points. 
Figure 6. Summary of the main features of TNBC preclinical models. (A) Suggested 
suitability for different aspects of therapy development, demonstrating evident 
complementarity of the models for TNBC drug discovery and validation. (B) Timeline of 
TNBC tumor progression indicating main differential features between 4T1 and MDA-
MB231-Luc regarding primary tumor, including stroma and metastatic sites (CAA: cancer-
associated adipocytes, EPR: enhanced permeability and retention effect, G-CSF: granulocyte 
colony-stimulating factor, GPC: glycerylphosphorylcholine, TGA: triacylglycerol). 
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Abbreviation List 
6-TG:  6-thioguanine 
18F-FDG: 18-Fluorodeoxyglucose 
ALN:  Axillary Lymph Node(s) 
BC:  Breast Cancer 
BCAA:  Branched Amino Acids 
BLI:  Bioluminescence Imaging 
CAA:  Cancer-Associated Adipocytes 
DFS:  Disease Free Survival 
EH:  Extramedullary Hematopoiesis 
ER:  Estrogen Receptor 
EPR:  Enhanced Permeability and Retention 
FBS:  Fetal Bovine Serum 
G-CSF:  Granulocyte-Colony Stimulating Factor 
GPC:  Glycerophosphorylcholine 
H&E:  Hematoxylin and Eosin 
HER2:  Human Epidermal Growth Factor Receptor 2 
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ILN:  Inguinal Lymph Node 
LDL:  Low Density Lipoprotein 
MDR:  Multi-Drug Resistance 
MPC:   Myeloid Precursor Cell 
NOD/SCID: Non-Obese Diabetic/Severe Combined Immunodeficiency 
NLR:  Neutrophil-to-Lymphocyte Ratio 
NTA:  Nanoparticle-Tracking Analysis 
OPLS-DA: Orthogonal Projections to Latent Structures Discriminant Analysis  
PR:  Progesterone Receptor 
PET/CT:  Positron Emission Tomography/Computed Tomography  
TAG:  Triacylglycerol 
TNBC:  Triple Negative Breast Cancer 
 
This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
Triple-negative breast cancer (TNBC), an aggressive, metastatic, and recurrent 
breast cancer subtype, currently lacks adequately described spontaneously 
metastatic preclinical models that faithfully reproduce the clinical scenario. Here, the 
authors provide an in-depth comparative analysis of two preclinical spontaneously 
metastatic TNBC orthotopic models, MDA-MB-231-Luc and 4T1. The results reveal a 
metastatic switch in both models with immune system activation and serum protein 
profile reconfiguration, which may support resistance to treatment and recurrence in 
TNBC. The authors also identify critical functional biomarkers and metabolomic 
signatures for metastatic progression that may facilitate the development of anti-
cancer therapeutics. 
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